Abdera leverages its Radio Optimized Vector Engineering (ROVEr™) platform to design heavy‑chain‑only, antibody‑based radiopharmaceuticals engineered for optimal pharmacokinetics and radioisotope delivery. The company aims to improve therapeutic index by pairing engineered antibodies with alpha or beta emitting isotopes to selectively destroy tumor cells while sparing healthy tissue. Abdera’s lead program targets DLL3 for small cell lung cancer and other solid tumors and is advancing through preclinical development with an IND expected in 2024. The company says it has generated promising proof‑of‑concept data across tumor models and is building a pipeline against additional undisclosed cancer targets. Abdera is led by an experienced team spanning biologics, radiochemistry and oncology drug development. The company is based in Menlo Park, California and Vancouver, British Columbia.

Total raised

$142M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2023